A New Weight Loss Hope: Wegovy's Bigger Dose Gets Green Light in Europe

The European Medicines Agency (EMA) has given the green light to Novo Nordisk's higher dose of Wegovy, marking a significant milestone for individuals battling weight issues.

Key Approval and Innovations

• The EMA's committee has approved the new dose, semaglutide 7.2 mg.
• Novo Nordisk is also seeking approval for a single-dose device to simplify administration.

Impressive Weight Loss Results

• Wegovy is already recognized for its weight-loss benefits, but the new dose delivers even better outcomes.
• Clinical trials showed an average weight loss of 20.7% over 72 weeks.
• Beyond aesthetics, weight loss can reduce the risk of heart attacks, strokes, and arthritis-related knee pain.

Study Highlights: STEP UP and STEP UP T2D

• One in three participants without diabetes lost 25% or more of their weight.
• The majority of weight lost was fat, not muscle, ensuring strength retention.

Global Impact and Future Prospects

• The approval isn't limited to Europe; the U.S., U.K., and other countries are also reviewing the new dose.
• In the U.S., Novo Nordisk has submitted the dose to the FDA and received a priority review voucher, potentially speeding up approval.

Market Reaction

• Novo Nordisk's shares saw a modest increase of 0.05%, reflecting cautious optimism.